Returning for its 7th year, the RAS-Targeted Drug Development Summit remains the only industry-focused meeting dedicated to targeting all RAS mutations in the fight against a wide array of cancers.

The 2025 summit is showcasing forward thinking RAS leaders with brand new innovations, from degraders, cell therapies, vaccines, small molecule inhibitors and more, to target G12C, G12D, Q61, NRAS – mutations and beyond.

With Revolution Medicines dosing their first subject in phase III NSCLC trial, we are now more than ever witnessing this industry make great strides. However, treating RAS mutant cancers remains no easy feat, as knowledge gaps persist in improving the durability of response, tackling emerging resistance mechanisms and informing combination strategies to improve the standard-of care for patients in need.

Join Pfizer, Amgen, PAQ Therapeutics, Aethon Therapeutics, and many others at the 7th RAS-Targeted Drug Development Summit to gain a wealth of actionable insights across the end-to-end drug development pipeline for RAS-targeting drugs.

See the event details here.